Data from a systemic review suggest that pulmonary embolism and deep-vein thrombosis do not necessarily have the same etiology.

The factor V Leiden (FVL) mutation is associated with a greater risk for deep vein thrombosis (DVT) than for pulmonary embolism (PE); this observation is paradoxical because most pulmonary emboli are thought to arise from DVT. However, factors other than FVL might increase the risk for one type of thrombosis versus another.

The drug significantly reduced high cardiac output and duration of epistaxis in a small study of patients with HHT.

Hereditary hemorrhagic telangiectasia (HHT) is characterized by repeated episodes of epistaxis; iron-deficiency anemia; telangiectasias; and arteriovenous malformations (AVMs) in the lungs, liver, gastrointestinal tract, and brain. Occasionally, multiple AVMs are located in the liver, resulting in extensive hepatic shunting and high-output cardiac failure. Aside from liver transplantation, few other options are available for patients with this complication. However, there might be a role for agents that target vasculogenesis, such as inhibitors of vascular endothelial growth factor (VEGF).

Reprogrammed T Cells Effective for Relapsed or Refractory B-Cell Malignancies

Six of eight patients with advanced, progressive B-cell lymphoma or chronic lymphocytic leukemia responded to molecularly reprogrammed targeted autologous T cells.

Biomarkers Predict Outcome of Graft-Versus-Host Disease

A six-protein biomarker panel predicted mortality and response to GVHD therapy.

A limiting factor in allogeneic hematopoietic cell transplantation is the development of graft-versus-host disease (GVHD). Having the ability to predict response to GVHD-treatment and survival might improve transplant outcomes.